Friday, August 15, 2014 7:07:52 PM
I read the celltex issue. Celltex was
claiming that the cells were "minimally manipulated" which fall under a less strict regulation with the FDA which is stated in the email I posted.
The FDA said otherwise.
Myocell is considered more than minimally manipulated in a lab where it would require pre market approval with results from a phase 3 trial under the BLA process. It's all in the body of the email I posted.
I said autologous stem cells being a potentially smaller biologic trial not all biologic trials are smaller
Mesoblast is an allogeneic stem cell direct competitor of bioheart.
They have a 1700 patient trial.
Cardio3 is an autologous competitor with a smaller trial more on par with Bioheart's trial size.
What's not to understand ?
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM